Randomized, sham-controlled trial results in dry AMD
At 30 weeks, patients treated with MacuMira gained an average of 10.4 more ETDRS letters of visual acuity and 0.25 log units more contrast sensitivity than the sham group (both p<0.001). Source: Parkinson KM, et al. Int J Retina Vitreous. 2023;9:36.
Format
PNG
Quelle:
MacuMira Medical Devices Inc.